Zymeworks Stock Price, News & Analysis (NYSE:ZYME)

$10.27 0.32 (3.22 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$9.95
Today's Range$10.00 - $10.34
52-Week Range$6.25 - $14.25
Volume7,998 shs
Average Volume16,923 shs
Market Capitalization$260.77 million
P/E Ratio-4.52
Dividend YieldN/A
BetaN/A

About Zymeworks (NYSE:ZYME)

Zymeworks logoZymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:ZYME
CUSIPN/A
Phone+1-604-6781388

Debt

Debt-to-Equity RatioN/A
Current Ratio4.57%
Quick Ratio4.57%

Price-To-Earnings

Trailing P/E Ratio-4.52422907488987
Forward P/E Ratio-3.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$11 million
Price / Sales23.70
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($2.27)
Net Income$-33,800,000.00
Net Margins-1,387.89%
Return on Equity-117.85%
Return on Assets-54.48%

Miscellaneous

Employees136
Outstanding Shares25,380,000

Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.09. Zymeworks had a negative net margin of 1,387.89% and a negative return on equity of 117.85%. View Zymeworks' Earnings History.

When will Zymeworks make its next earnings announcement?

Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Zymeworks.

Where is Zymeworks' stock going? Where will Zymeworks' stock price be in 2018?

6 equities research analysts have issued twelve-month target prices for Zymeworks' shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Zymeworks' stock price to reach $16.00 in the next twelve months. View Analyst Ratings for Zymeworks.

Who are some of Zymeworks' key competitors?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:

  • Nick Bedford, Chairman of the Board
  • Ali Tehrani Ph.D., President, Chief Executive Officer, Director
  • Neil Klompas, Chief Financial Officer
  • Surjit Dixit Ph.D., Chief Technology Officer
  • Diana Hausman M.D., Chief Medical Officer (Age 52)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

How do I buy Zymeworks stock?

Shares of Zymeworks can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of Zymeworks stock can currently be purchased for approximately $10.27.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $260.77 million and generates $11 million in revenue each year. The company earns $-33,800,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Zymeworks employs 136 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 8th Ave W Suite 540, VANCOUVER, BC V6H 3V9, Canada. The company can be reached via phone at +1-604-6781388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (ZYME)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zymeworks (NYSE:ZYME) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.332.333.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$16.00$19.00
Price Target Upside: 100.50% upside100.50% upside100.50% upside45.48% upside

Zymeworks (NYSE:ZYME) Consensus Price Target History

Price Target History for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE:ZYME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/30/2017CormarkReiterated RatingBuyMediumView Rating Details
9/7/2017ScotiabankDowngradeOverweight -> UnderweightHighView Rating Details
9/7/2017BarclaysReiterated RatingOverweight -> Underweight$8.00HighView Rating Details
5/23/2017CitigroupInitiated CoverageBuy -> Buy$18.00LowView Rating Details
5/23/2017Wells Fargo & CoInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
5/23/2017Canaccord GenuityInitiated CoverageBuy -> Buy$18.00LowView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Zymeworks (NYSE:ZYME) Earnings History and Estimates Chart

Earnings by Quarter for Zymeworks (NYSE:ZYME)

Zymeworks (NYSE ZYME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
11/8/2017Q3 2017($0.74)($0.65)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.63)ViewN/AView Earnings Details
5/15/2017Q1($1.13)$0.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Zymeworks (NYSE:ZYME) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.09 EPS
Next Year EPS Consensus Estimate: $-2.6 EPS

Dividends

Dividend History for Zymeworks (NYSE:ZYME)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zymeworks (NYSE ZYME)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Zymeworks (NYSE ZYME) News Headlines

Source:
DateHeadline
Contrasting Zymeworks (ZYME) and Its CompetitorsContrasting Zymeworks (ZYME) and Its Competitors
www.americanbankingnews.com - January 17 at 3:12 AM
-$0.62 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter-$0.62 Earnings Per Share Expected for Zymeworks Inc (ZYME) This Quarter
www.americanbankingnews.com - January 16 at 9:30 AM
Zymeworks (ZYME) Rating Lowered to Hold at Zacks Investment ResearchZymeworks (ZYME) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
Financial Survey: Verastem (VSTM) and Zymeworks (ZYME)Financial Survey: Verastem (VSTM) and Zymeworks (ZYME)
www.americanbankingnews.com - January 12 at 8:18 AM
Zymeworks Inc (ZYME) Receives Consensus Recommendation of "Hold" from AnalystsZymeworks Inc (ZYME) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 10 at 8:14 AM
Critical Analysis: Zymeworks (ZYME) and The CompetitionCritical Analysis: Zymeworks (ZYME) and The Competition
www.americanbankingnews.com - January 9 at 5:10 AM
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 PrioritiesZymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities
finance.yahoo.com - January 7 at 7:37 PM
Zymeworks Inc (ZYME) Given Average Rating of "Hold" by AnalystsZymeworks Inc (ZYME) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM
Applied BioMath, LLC to Sponsor and Present at PepTalk: The Protein Science WeekApplied BioMath, LLC to Sponsor and Present at PepTalk: The Protein Science Week
www.prnewswire.com - December 12 at 6:18 PM
Head-To-Head Survey: Affimed (AFMD) & Zymeworks (ZYME)Head-To-Head Survey: Affimed (AFMD) & Zymeworks (ZYME)
www.americanbankingnews.com - November 28 at 5:46 PM
Zymeworks Inc. (ZYME) Receives Average Recommendation of "Hold" from BrokeragesZymeworks Inc. (ZYME) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 21 at 8:24 AM

SEC Filings

Zymeworks (NYSE:ZYME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zymeworks (NYSE:ZYME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zymeworks (NYSE ZYME) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.